A respiratory bacterium that causes pneumonia and sinus infections has turned up in an unexpected place—and it might be making Alzheimer's disease worse.
Researchers at Cedars-Sinai Medical Center have discovered that Chlamydia pneumoniae, one of the most common causes of respiratory infections, can reach the retina and trigger immune responses linked to inflammation, nerve cell death, and cognitive decline. This is the first time scientists have established a direct connection between this specific bacterium in the eye and Alzheimer's pathology.
The findings, from a study of 104 individuals across three cognitive groups, revealed that bacterial levels in the retina and brain were significantly higher in Alzheimer's patients compared to cognitively normal individuals. More striking: the bacterial load correlated directly with the severity of brain pathology and the intensity of cognitive decline.
Dr. Maya Koronyo-Hamaoui, Professor of Neurosurgery and senior author of the study, emphasized an important clinical implication: "The eye is a surrogate for the brain." That means retinal imaging could provide a noninvasive way to identify disease risk and monitor progression—something that's currently only possible through expensive brain scans or invasive spinal taps.
The research team didn't stop at correlation. They extended their work to human neurons and laboratory mice with Alzheimer's disease to demonstrate causation. When they infected these models, they observed increased inflammation, nerve cell death, cognitive decline, and production of amyloid-beta—the protein that forms the plaques characteristic of Alzheimer's.
There's another layer to this story: the bacteria seemed to hit hardest in people carrying the APOE4 gene variant, a well-established genetic risk factor for Alzheimer's. This suggests that bacterial infection might interact with genetic predisposition to accelerate neurodegeneration.
Now, before you rush to get antibiotics for every sinus infection, we need to talk about limitations. This is observational research—we've found an association and demonstrated a biological mechanism, but we don't yet know if treating the bacterial infection would prevent or slow Alzheimer's. That's the next frontier.
Dr. Timothy Crother, co-corresponding author, noted that this discovery "raises the possibility of targeting the infection-inflammation connection" as a treatment strategy. But clinical trials are needed to determine whether antimicrobial approaches would actually work in humans.
